Ilsung Pharmaceuticals Co., Ltd. (003120.KS)
KRW 15970.0
(-0.19%)
KRW 15970.0
(-0.19%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 34.71 Billion KRW | 24.27% |
| 2022 | 27.93 Billion KRW | 73.13% |
| 2021 | 16.13 Billion KRW | 22.4% |
| 2020 | 13.18 Billion KRW | -27.43% |
| 2019 | 18.16 Billion KRW | -19.6% |
| 2018 | 22.59 Billion KRW | -13.91% |
| 2017 | 26.24 Billion KRW | 5.02% |
| 2016 | 24.98 Billion KRW | 12.76% |
| 2015 | 22.16 Billion KRW | 3.94% |
| 2014 | 21.32 Billion KRW | 1.13% |
| 2013 | 21.08 Billion KRW | -0.87% |
| 2012 | 21.26 Billion KRW | -13.05% |
| 2011 | 24.45 Billion KRW | -0.2% |
| 2010 | 24.5 Billion KRW | -20.35% |
| 2009 | 30.76 Billion KRW | -16.9% |
| 2008 | 37.02 Billion KRW | -11.43% |
| 2007 | 41.8 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 5.89 Billion KRW | -34.33% |
| 2024 Q2 | 5.78 Billion KRW | -1.76% |
| 2023 FY | 34.71 Billion KRW | 24.27% |
| 2023 Q1 | 8.77 Billion KRW | 4.54% |
| 2023 Q4 | 8.97 Billion KRW | 19.35% |
| 2023 Q3 | 7.51 Billion KRW | -30.3% |
| 2023 Q2 | 10.78 Billion KRW | 22.92% |
| 2022 Q1 | 6.15 Billion KRW | 17.45% |
| 2022 Q3 | 7.45 Billion KRW | 25.75% |
| 2022 Q4 | 8.39 Billion KRW | 12.56% |
| 2022 Q2 | 5.92 Billion KRW | -3.66% |
| 2022 FY | 27.93 Billion KRW | 73.13% |
| 2021 Q4 | 5.24 Billion KRW | 27.36% |
| 2021 FY | 16.13 Billion KRW | 22.4% |
| 2021 Q1 | 3.17 Billion KRW | 15.19% |
| 2021 Q2 | 3.6 Billion KRW | 13.52% |
| 2021 Q3 | 4.11 Billion KRW | 14.14% |
| 2020 Q1 | 4.23 Billion KRW | -18.42% |
| 2020 Q3 | 3.13 Billion KRW | 2.21% |
| 2020 Q2 | 3.06 Billion KRW | -27.57% |
| 2020 FY | 13.18 Billion KRW | -27.43% |
| 2020 Q4 | 2.75 Billion KRW | -11.96% |
| 2019 Q3 | 4.08 Billion KRW | -6.19% |
| 2019 FY | 18.16 Billion KRW | -19.6% |
| 2019 Q1 | 4.53 Billion KRW | -24.14% |
| 2019 Q4 | 5.18 Billion KRW | 26.79% |
| 2019 Q2 | 4.35 Billion KRW | -3.8% |
| 2018 Q2 | 5.56 Billion KRW | -14.37% |
| 2018 Q1 | 6.5 Billion KRW | 4.09% |
| 2018 FY | 22.59 Billion KRW | -13.91% |
| 2018 Q3 | 4.54 Billion KRW | -18.31% |
| 2018 Q4 | 5.97 Billion KRW | 31.31% |
| 2017 Q1 | 6.96 Billion KRW | 9.28% |
| 2017 Q4 | 6.24 Billion KRW | -1.67% |
| 2017 Q3 | 6.35 Billion KRW | -4.83% |
| 2017 Q2 | 6.67 Billion KRW | -4.19% |
| 2017 FY | 26.24 Billion KRW | 5.02% |
| 2016 Q1 | 5.54 Billion KRW | 10.27% |
| 2016 FY | 24.98 Billion KRW | 12.76% |
| 2016 Q4 | 6.37 Billion KRW | -8.45% |
| 2016 Q3 | 6.96 Billion KRW | 14.17% |
| 2016 Q2 | 6.1 Billion KRW | 9.93% |
| 2015 FY | 22.16 Billion KRW | 3.94% |
| 2015 Q4 | 5.03 Billion KRW | -1.98% |
| 2015 Q3 | 5.13 Billion KRW | -15.83% |
| 2015 Q2 | 6.09 Billion KRW | 3.42% |
| 2015 Q1 | 5.89 Billion KRW | 6.31% |
| 2014 FY | 21.32 Billion KRW | 1.13% |
| 2014 Q1 | 6 Billion KRW | 26.36% |
| 2014 Q4 | 5.54 Billion KRW | 10.79% |
| 2014 Q3 | 5 Billion KRW | 5.12% |
| 2014 Q2 | 4.76 Billion KRW | -20.66% |
| 2013 Q3 | 4.8 Billion KRW | -17.57% |
| 2013 Q4 | 4.75 Billion KRW | -1.12% |
| 2013 FY | 21.08 Billion KRW | -0.87% |
| 2013 Q1 | 5.69 Billion KRW | -30.65% |
| 2013 Q2 | 5.82 Billion KRW | 2.33% |
| 2012 Q4 | 8.21 Billion KRW | 201.47% |
| 2012 Q2 | 4.17 Billion KRW | -32.05% |
| 2012 FY | 21.26 Billion KRW | -13.05% |
| 2012 Q3 | 2.72 Billion KRW | -34.8% |
| 2012 Q1 | 6.15 Billion KRW | 9.59% |
| 2011 Q4 | 5.61 Billion KRW | -2.37% |
| 2011 Q1 | 6.35 Billion KRW | 26.88% |
| 2011 Q2 | 6.74 Billion KRW | 6.23% |
| 2011 FY | 24.45 Billion KRW | -0.2% |
| 2011 Q3 | 5.74 Billion KRW | -14.8% |
| 2010 FY | 24.5 Billion KRW | -20.35% |
| 2010 Q4 | 5 Billion KRW | -15.96% |
| 2010 Q3 | 5.95 Billion KRW | -0.43% |
| 2010 Q2 | 5.98 Billion KRW | -20.9% |
| 2010 Q1 | 7.56 Billion KRW | -11.55% |
| 2009 Q2 | 6.39 Billion KRW | -24.94% |
| 2009 Q3 | 7.3 Billion KRW | 14.35% |
| 2009 Q1 | 8.51 Billion KRW | 4.44% |
| 2009 Q4 | 8.55 Billion KRW | 16.97% |
| 2009 FY | 30.76 Billion KRW | -16.9% |
| 2008 Q4 | 8.15 Billion KRW | -8.76% |
| 2008 Q3 | 8.93 Billion KRW | -7.7% |
| 2008 Q2 | 9.68 Billion KRW | -5.59% |
| 2008 Q1 | 10.25 Billion KRW | -3.95% |
| 2008 FY | 37.02 Billion KRW | -11.43% |
| 2007 FY | 41.8 Billion KRW | 0.0% |
| 2007 Q4 | 10.67 Billion KRW | 16.07% |
| 2007 Q3 | 9.19 Billion KRW | -20.4% |
| 2007 Q2 | 11.55 Billion KRW | 11.38% |
| 2007 Q1 | 10.37 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 25.351% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 90.466% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 82.545% |
| HANDOK Inc. | 151.36 Billion KRW | 77.065% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | 48.358% |
| Yuhan Corporation | 564.5 Billion KRW | 93.85% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 89.226% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -46.19% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 95.847% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | 53.737% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 82.552% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | 14.597% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | 63.27% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 75.354% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 25.351% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | 54.808% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 388.203% |
| JW Holdings Corporation | 446.15 Billion KRW | 92.219% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 83.273% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 94.703% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 89.658% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 55.843% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | 53.859% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | 51.925% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 81.114% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 25.351% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 88.237% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 94.906% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 89.658% |
| Yuhan Corporation | 564.5 Billion KRW | 93.85% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 82.799% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | 51.063% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 64.943% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 89.658% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 76.204% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 79.99% |
| CKD Bio Corp. | 5.01 Billion KRW | -592.888% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 86.345% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 81.145% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | 64.621% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 55.843% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 90.655% |
| Boryung Corporation | 333.26 Billion KRW | 89.583% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | 30.632% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 82.552% |
| JW Lifescience Corporation | 51.32 Billion KRW | 32.361% |